Optimizing pregnancy outcomes in intrauterine insemination cycles by stratifying pre-wash total motile count and patient-specific factors: a patient counseling tool

PURPOSE

The purpose of this study is to clarify which pre-wash total motile count are associated with improved clinical pregnancy rate (CPR) and live birth rate (LBR) based on maternal age, AMH level, stimulation regimen, and infertility diagnosis.

METHODS

This was a retrospective cohort study of first completed IUI cycles at two academic fertility centers from 5/2015 to 9/2019. Cycles were stratified by pre-wash TMC, maternal age, AMH level, stimulation regimen, and infertility diagnosis. The primary outcome was CPR and secondary outcomes were live birth and miscarriage.

RESULTS

One thousand one hundred fifty-four cycles were analyzed. Of the 162 cycles that resulted in a CPR (14.0%), most had an insemination TMC > 20 million. Compared to TMC > 20 million, there was no difference in CPR or LBR for lower TMC categories, excluding the TMC < 2 million group, in which there were no pregnancies. When TMC was stratified by deciles, there was also no difference in CPR and LBR, including within the lowest decile (TMC 0.09-8.6 million). Younger age and higher ovarian reserve parameters were associated with higher pregnancy and LBR when stratified by TMC. There was no difference in pregnancy and LBR when considering different stimulation protocols.

CONCLUSIONS

Our data suggest that pregnancy and LBR are equivalent above a TMC of 2 million. Data stratified by TMC and patient parameters can be used to counsel patients pursuing ART.

Characterizing the follicular fluid metabolome: quantifying the correlation across follicles and differences with the serum metabolome

OBJECTIVE

To compare the variability in metabolomes between the serum and follicular fluid, as well as across 3 dominant follicles.

DESIGN

Prospective cohort study.

SETTING

An academic fertility clinic in the northeastern United States, 2005-2015.

PATIENTS

One hundred thirty-five women undergoing in vitro fertilization treatment who provided a serum sample during ovarian stimulation and up to 3 follicular fluid samples during oocyte retrieval.

INTERVENTION(S)

None.

MAIN OUTCOME MEASURE(S)

Samples were analyzed using liquid chromatography with high-resolution mass spectrometry and 2 chromatography columns (C18 hydrophobic negative and hydrophilic interaction chromatography [HILIC] positive). We calculated overall, feature-specific, and subject-specific correlation coefficients to describe how strongly the intensity of overlapping metabolic features were associated between the serum and follicular fluid and between the 1st-2nd, 1st-3rd, and 2nd-3rd follicles. Feature-specific correlations were adjusted for age, body mass index, infertility diagnosis, ovarian stimulation protocol, and year.

RESULT(S)

From the C18-negative column and the high-resolution mass spectrometry, 7,830 serum features and 10,790 follicular fluid features were detected in ≥20% of samples. After screening retention times and checking for 1:1 matching, 1,928 features overlapped between the 2 metabolomes. From the HILIC-positive column and the high-resolution mass spectrometry, after applying the same exclusion criteria, there were 9,074 serum features, 5,542 follicular fluid features, and 1,149 features that overlapped. When comparing the feature intensity of overlapping metabolites in the serum and the follicular fluid, the overall (C18, 0.45; HILIC, 0.63), median feature-specific (C18, 0.35; HILIC, 0.37), and median subject-specific (C18, 0.42; HILIC, 0.59) correlations were low to moderate. In contrast, among the overlapping features across all 3 follicles, the overall (C18, all 0.99; HILIC, all 0.99), median feature-specific (C18, 0.74-0.81; HILIC, 0.79-0.85), and median subject-specific (C18, 0.88-0.89; HILIC, 0.90-0.91) correlations between follicular fluid metabolomics features within a woman were high.

CONCLUSION(S)

We observed minimal overlap and weak-to-moderate correlation between metabolomic features in the serum and follicular fluid but a large overlap and strong correlation between metabolomic features across follicles within a woman. The follicular fluid appears to represent a novel matrix, distinct from serum, which may be a rich source of biologic predictors of female fertility and reproductive outcomes.

Using artificial intelligence to avoid human error in identifying embryos: a retrospective cohort study

PURPOSE

To determine whether convolutional neural networks (CNN) can be used to accurately ascertain the patient identity (ID) of cleavage and blastocyst stage embryos based on image data alone.

METHODS

A CNN model was trained and validated over three replicates on a retrospective cohort of 4889 time-lapse embryo images. The algorithm processed embryo images for each patient and produced a unique identification key that was associated with the patient ID at a timepoint on day 3 (~ 65 hours post-insemination (hpi)) and day 5 (~ 105 hpi) forming our data library. When the algorithm evaluated embryos at a later timepoint on day 3 (~ 70 hpi) and day 5 (~ 110 hpi), it generates another key that was matched with the patient's unique key available in the library. This approach was tested using 400 patient embryo cohorts on day 3 and day 5 and number of correct embryo identifications with the CNN algorithm was measured.

RESULTS

CNN technology matched the patient identification within random pools of 8 patient embryo cohorts on day 3 with 100% accuracy (n = 400 patients; 3 replicates). For day 5 embryo cohorts, the accuracy within random pools of 8 patients was 100% (n = 400 patients; 3 replicates).

CONCLUSIONS

This study describes an artificial intelligence-based approach for embryo identification. This technology offers a robust witnessing step based on unique morphological features of each embryo. This technology can be integrated with existing imaging systems and laboratory protocols to improve specimen tracking.

Association of preconception mixtures of phenol and phthalate metabolites with birthweight among subfertile couples

Although parental preconception exposure to some phenols and phthalates have been associated with reduced birthweight, few studies have examined these chemicals as complex mixtures.

Pregnancy urinary concentrations of bisphenol A, parabens and other phenols in relation to serum levels of lipid biomarkers: Results from the EARTH study

The epidemiologic literature on associations between urinary phenol concentrations and lipid profiles during pregnancy is limited. We examined whether urinary concentrations of phenol and phenol replacement biomarkers were associated with serum lipid levels among pregnant women. This cross-sectional study included 175 women attending the Massachusetts General Hospital Fertility Center who enrolled in the Environment and Reproductive Health (EARTH) Study between 2005 and 2017 and had data available on urinary phenol biomarkers and serum lipids during pregnancy. We used linear regression models to assess the relationship between groups of urinary phenol and phenol replacement biomarkers and serum lipid levels [total cholesterol, high density lipoprotein (HDL), non-HDL, low-density lipoprotein (LDL) cholesterol, and triglycerides], while adjusting for age at sample collection, pre-pregnancy BMI, education, race, infertility diagnosis, cycle type, number of fetuses, trimester and specific gravity. In adjusted models, pregnant women with urinary propylparaben concentrations in the highest tertile had 10% [22 (95% CI = 5, 40) mg/dL], 12% [19 (95% CI = 2, 36) mg/dL] and 16% [19 (95% CI = 3, 35) mg/dL] higher mean total, non-HDL and LDL cholesterol, respectively, compared to women with concentrations in the lowest tertile. Similar elevations were observed for urinary bisphenol A concentrations. Urinary bisphenol S, benzophenone-3, triclosan, methylparaben, ethylparaben, and butylparaben were unrelated to serum lipids. Among pregnant women, urinary concentrations of bisphenol A and propylparaben were associated with higher serum levels of total, non-HDL and LDL cholesterol.

Reproductive medicine in the face of climate change: a call for prevention through leadership

Climate change has led to a multitude of ecological disruptions and downstream reproductive health consequences that impair our reproductive capacity and, in turn, harm the health and survival of future generations. Atmospheric changes, driven by anthropogenic emissions, expose global populations to droughts, heat waves, rising sea levels, and extreme weather events-posing major threats to public health and exacerbating environmental health disparities. Existing evidence demonstrates the potential for climate-driven events to impact reproductive health outcomes, yet very few studies have explored this relationship. Recently, the American Society for Reproductive Medicine, the American College of Obstetricians and Gynecologists, and the International Federation of Gynecology and Obstetrics released position statements regarding reproductive health and environmental exposures. Unfortunately, such initiatives have yielded little action within the health care system. To address this stagnation, health care workers must meld research findings into actionable preventive medicine strategies and transition to a more action-oriented approach to address the climate crisis. The objective of this article is to elucidate the urgency of the climate crisis in relation to reproductive health and push the health care workers to recognize their intrinsic opportunity as leaders in climate action at local, state, national, and international levels. We call on health care organizations and health care workers to leverage their inherent positions as climate action leaders to increase climate resilience and mitigate climate-related adverse reproductive health outcomes.

P-557 Fresh Transfer with Supernumerary PGT-A Biopsy: The Best of Both Worlds

Study question

What is difference in time to pregnancy for patients between 35-40 years who undergo fresh versus frozen-thawed embryo transfers with or without PGT-A?

Summary answer

Patients undergoing fresh embryo transfer (ET) had a shorter time to pregnancy within the same cycle compared to patients electing for freeze-all cycles.

What is known already

When comparing clinical pregnancy rates following fresh versus frozen-thawed embryo transfers, multiple studies have shown a higher clinical pregnancy rate among frozen-thawed embryo transfers compared to fresh embryo transfers. Particularly for patients over 35 years, there has been a growing national trend towards elective freeze-all cycles, for reasons such as to pursue preimplantation genetic testing for aneuploidy (PGT-A). While PGT-A testing can be effective in reducing miscarriage in patients age 38-40, there is limited studies evaluating time to pregnancy within this population, especially in the context of each passing month’s effect on fertility.

Study design, size, duration

Retrospective review was performed for 697 IVF cycles and 881 transfers from January 2016 – December 2021 at a single academic fertility center in Boston, Massachusetts. Two-tailed t-tests and analysis of variance (ANOVA) were used to compare differences, with p-value less than 0.05 set for statistical significance. All PGT-A testing as performed using a modified FAST-SeqS next generation sequencing method (Invitae, San Francisco, CA).

Participants/materials, setting, methods

Cycle characteristic of patients between 35-40 were categorized to four groups: Fresh ET with PGT-A of supernumerary embryos (82 transfers), Fresh ET without PGT-A (526 transfers), Freeze-all cycle with PGT-A (223 transfers), and Freeze-all cycle without PGT-A (50 transfers). All averages were calculated within one IVF cycle with a single cohort of embryos. Time to pregnancy was calculated in days from day of retrieval to positive serum beta-human chorionic gonadotropin (bHCG).

Main results and the role of chance

Among the 881 transfers, 478 had fresh ETs and 403 had frozen-thawed ETs with or without PGT-A respectively. When comparing fresh and freeze-all cycles, there was no difference in average numbers of transfers performed to achieve a clinical pregnancy (1.27 fresh vs 1.25 freeze-all, p = 0.56). For patients who didn’t elect for PGT-A, there was no difference in number of embryos transferred (1.86 for fresh versus 2.06 for freeze-all, p = 0.54). For patients who elected for PGT-A, the average number of embryos transferred was higher for patients that opted for fresh transfer over freeze-all (1.67 for fresh ET with PGT-A of supernumerary embryos versus 1.24 for freeze-all PGT-A, p = 0.0025). Average days from oocyte retrieval to pregnancy was significantly lower for all fresh ETs (28.8 days for fresh ET without biopsy, 26.6 days for fresh ET with biopsy of supernumerary embryos, p &lt; 0.0001) compared to all freeze-all transfers (110.9 days for freeze-all ET without biopsy, 119.5 days for freeze-all ET with biopsy, p &lt; 0.0001). This delay in time to pregnancy is partially attributed to pending genetic testing results, however, these results usually return in 2-3 weeks, which does not account for the near 3-month delay in time to pregnancy among freeze-all cycles.

Limitations, reasons for caution

These retrospective findings were of all women who achieved pregnancy from one retrieval. These results are not reflective of the patients who needed to undergo multiple cycles to achieve pregnancy, or patients who never achieved pregnancy.

Wider implications of the findings

These findings suggest that PGT-A may be offered to patients &gt; 35 to minimize the number of embryos for transfer. Patients opting for a fresh transfer of an untested embryo and biopsy of supernumerary embryos had a nearly 3-month shorter time to pregnancy than those electing for a freeze-all cycle

Trial registration number

not applicable

O-184 The impact of cryopreserved sperm on Intrauterine Insemination (IUI) outcomes: Is frozen as good as fresh?

Study question

Are the outcomes of IUI cycles [with or without ovarian stimulation (OS)] comparable when frozen instead of fresh-ejaculated sperm is utilized?

Summary answer

Overall, clinical outcomes did not differ significantly between frozen and fresh sperm IUI cycles, although specific subgroups might benefit from fresh sperm utilization.

What is known already

At present, data from animal studies point towards less favorable outcomes with frozen sperm utilization, implicating cryopreservation-induced damages to the cytoskeleton, DNA, and acrosome leading to adverse effects on spermatozoa’s motility, viability, and ability to fuse with the oocyte. Assisted Reproductive Technology (ART) data, mostly focusing on severe male factor infertility diagnoses, suggest no major differences between in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles utilizing frozen over fresh sperm, often surgically extracted. Nevertheless, contemporary data from IUI(±OS) cycles are still scarce.

Study design, size, duration

Data from 5335 IUI(±OS) cycles (time-period: 01/2004-12/2021) from a large academic fertility center were retrospectively reviewed. Cycles were stratified in two groups based on utilization of frozen instead of fresh-ejaculated sperm for the IUI [FROZEN (n = 1871, all infertility diagnoses), and FRESH (n = 3464, idiopathic infertility diagnosis only), respectively]. Cycle outcomes were compared between groups.

Participants/materials, setting, methods

Participants: women seeking IUI (±OS) treatments.

Outcome Measures: HCG-positivity, clinical pregnancy (CP), spontaneous abortion (SAB) rates. Initial analysis included all cycles irrespective of OS regimen.  Cycles were then stratified by OS regimen into three subgroups [injectable gonadotropins, oral medications (OM): clomiphene-citrate and letrozole, and unstimulated/natural]. Odds ratios (OR) for all relevant outcomes were calculated utilizing logistic regression and adjusted for maternal age, day-3 FSH, and OS regimen. Time-to-pregnancy and first-cycle only analyses were also performed.

Main results and the role of chance

Unadjusted HCG-positivity, and CP were lower in the FROZEN compared to the FRESH group (12.2% vs. 15.6%, p &lt; 0.001; 9.4% vs. 13.0%, p&lt;.001, respectively), which persisted only among OM after stratification (9.9% vs. 14.2% HCG-positivity, p=.030; 8.1% vs. 11.8% CPR, p=.041, for FROZEN compared to FRESH, respectively).

Among all cycles, adjOR(95%CI) for HCG-positivity and CP were respectively: 0.75(0.56-1.02), and 0.77(0.57-1.03), ref: FRESH). Following stratification by OS regimen, adjOR(95%CI) for HCG-positivity and CP showed no difference between groups among gonadotropin and natural cycles but favored the FRESH group in OM cycles [HCG-positivity: 0.55(0.30-0.99); CP: 0.49(0.25-0.95), ref.: FRESH]. SAB odds did not differ between groups among OM and natural cycles but were lower in the FROZEN compared to FRESH group among gonadotropin cycles [adjOR(95%CI): 0.13(0.02-0.98), ref.: FRESH]. However, regarding the latter comparison, numbers were small and the 95%CI wide.  When analysis was limited to first-cycles only and further stratified by OS regimen, the previously noted differences in CP and SAB odds no longer existed within the OS subgroups.

Nevetheless, time-to-conception was slightly longer in the FROZEN compared to the FRESH group (3.84 vs. 2.58 cycles, p&lt;.001).

Limitations, reasons for caution

Study is limited by its retrospective nature. The two groups differed somewhat in age, infertility diagnosis, utilized OS regimen, and as expected in total motile sperm counts. Despite the less favorable characteristics of the FROZEN group, no detrimental effect of sperm cryopreservation on IUI outcomes was noted.

Wider implications of the findings

Our study, the largest to date, showed no significant difference in IUI outcomes between cycles utilizing frozen instead of fresh-ejaculated sperm. Although, specific subgroups might benefit from fresh sperm utilization and time-to-pregnancy might be shorter with fresh over frozen sperm, patients should be counselled about the non-inferiority of frozen sperm.

Trial registration number

Not applicable

P-647 Intake of soy foods and soy isoflavones in relation to ovarian reserve among women presenting to a fertility center

Study question

Are soy food and isoflavone intakes associated with ovarian reserve as measured by antral follicle count (AFC)?

Summary answer

Within the observed range of intake, soy food or isoflavone consumptions are not associated with AFC.

What is known already

Phytoestrogens are structurally similar to 17β-estradiol, and bind to ER-α and ER-β in vitro resulting in weak estrogenic activity. Previous work in ruminants, felines and rodents has shown that exposure to phytoestrogens can have major adverse impacts on reproduction. However, findings of studies in humans suggest that soy foods and soy phytoestrogens may not have major deleterious impacts on reproductive hormone levels or reproductive outcomes, and could even be beneficial in couples undergoing infertility treatment.

Study design, size, duration

Women presenting to a large academic fertility center between April 2007 and December 2019 were invited to participate in the Environment and Reproductive Health (EARTH) Study, a prospective cohort study. Intake of 15 soy-based foods during the previous three months was obtained at baseline and intake of soy phytoestrogens was estimated from these reports. AFC was assessed with transvaginal ultrasound performed as part of diagnostic evaluation for infertility.

Participants/materials, setting, methods

We included 667 women who reported their soy food intake and had an AFC assessment. Women were divided in groups of increasing soy food and soy isoflavone intake with women who reported not consuming soy-based foods serving as the reference group. We evaluated the association of soy foods and soy isoflavones intake with AFC using Poisson regression models adjusting for confounders. Analyses were also stratified by age, BMI, and smoking status.

Main results and the role of chance

Women had median baseline age of 35.0 years and BMI of 23.4 kg/m2. Mean (range) intake of soy foods was 0.1 (0-7.4) servings/day, and mean (range) intake of isoflavones was 6 (0-166) mg/day, which is comparable to that of women in the general population of the USA. Intakes of soy foods or isoflavones were not related to AFC. The median (IQR) AFC for women who did not consume soy foods and women in the highest category of soy intake (&gt;0.45 servings/day, median 0.88 servings/day) were 12 (9, 18) and 13 (9, 19). After adjustment for potential confounders, the mean difference in AFC between women in the highest category of soy intake and women who did not consume soy was -0.5% (-6.6%, 6.1%). Soy food intake remained unrelated to AFC when intake was categorized using different cutoff values when intake was modeled as a continuous variable when departures from a linear association were considered, and when we excluded from analysis 76 women whose AFC ultrasound scan was performed before they completed the diet assessment. Soy intake was also unrelated to AFC within categories of age, BMI and smoking status. Findings for soy isoflavones mirrored those for soy-food intake.

Limitations, reasons for caution

Self-reported soy intake may have resulted in measurement error leading to attenuation of observed relations towards the null. Also, all participants were women presenting to a fertility center and therefore, findings may not be generalizable to women in the general population.

Wider implications of the findings

Our findings suggest soy food and isoflavone intakes within the ranges observed among women in the general population of the USA is unlikely to influence ovarian reserve in any meaningful way.

Trial registration number

Not applicable

P-342 The impact of Clomiphene Citrate (CC) on the endometrium in comparison to gonadotropins (Gn) in intrauterine-insemination treatments (IUI): Is it thinner and does it matter?

Study question

Utilizing patients as their own controls, does endometrial thickness (EMT) differ between CC/IUI and Gn/IUI? Does EMT differ between CC-cycles with and without associated conception?

Summary answer

Within-patient, CC resulted in thinner EMT compared to Gn. CC-cycles associated with conception compared to the ones without it, had thicker endometria.

What is known already

CC, unlike gonadotropins, may have an anti-estrogenic effect on the endometrium. Concerns exist that the thinning of the endometrium might be associated with altered endometrial development and receptivity. However, available data in CC cycles remain inconsistent, probably due to patient and protocol heterogeneity. Currently, it remains unclear whether CC treatments produce a thinner endometrium, compared to gonadotropins, in the same patient. Furthermore, it is uncertain whether such a difference, if one exists, has a consequential effect on IUI cycle outcomes.

Study design, size, duration

Design: retrospective.

Duration: 1/2004-9/2021

Cohort 1 utilized women as their own controls to evaluate CC’s impact on the endometrium and included all cycles from women who sought fertility treatments and initially underwent CC/IUI (CC1, n = 1252) followed by Gn/IUI (Gn1, n = 1307).

Cohort 2 included all cycles from women seeking fertility treatments at the same center that conceived following CC/IUI treatments (CC2, n = 686).

EMT was compared between groups (CC1 vs. Gn1, CC1 vs. CC2).

Participants/materials, setting, methods

Outcome measures:

Primary: EMT (mm).

Secondary: HCG-positivity (pos-HCGR), clinical pregnancy (CPR), and spontaneous abortion rates (SABR).

Statistics:

Regression analysis was used to calculate Odds Ratios (OR) with associated 95% confidence intervals (95%CI), adjusting for potential confounders [maternal age, Body Mass Index (BMI), prior parity, day of EMT measurement relative to trigger). Generalized estimating equations (GEE) model were utilized to account for multiple cycles per patient. P &lt; 0.05 was considered significant.

Main results and the role of chance

In cohort 1, despite CC1 exhibiting non-inferior ovarian response compared to Gn1 (as assessed by preovulatory follicular number), EMT was significantly thinner in CC1 compared to Gn1 [Median(IQR): 7.0(5.7-8.3) vs. 8.9(7.4-10.0), p&lt;.001]. When CC1 was compared to CC2 (CC conceiving), EMT was also thinner [Median(IQR): 7.0(5.7-8.3) vs. 7.5(6.2-9.0), for CC1 vs. CC2, respectively, p&lt;.001]. A higher percentage of CC1 compared to Gn1 cycles resulted in EMT≤7mm (48.9% vs. 16.7% , for CC1 vs. Gn, respectively; p&lt;.001). Most subsequent Gn cycles (82.8%), in the same women, resulted in thicker EMT compared to CC1. AdjOR, in generalized linear mixed models, suggested that CC2 when compared to CC1 cycles had thicker EMT [adjOR(95%CI): 1.81, (1.41,2.35), p&lt;.001].

Interestingly, clinical pregnancies were observed even when EMT was ≤4mm in both CC2 and Gn1 groups and SABR did not differ between cycles with EMT≤4mm and the ones with thicker EMT (2.5% vs. 11.5%, p=.258, in CC2; 0% and 12.3%, p=.544, in Gn1; SABR EMT ≤4 vs. 4 mm, respectively). GEE models suggested an association between EMT and CPR in CC cycles (CC1&CC2), [adjOR(95%CI): 1.12(1.07,1.18), p&lt;.001)] while in Gn1, no such association was observed.

Limitations, reasons for caution

Our study was limited by its retrospective design. Reflecting our selection criterion, in cohort 1, most CC cycles did not result in pregnancy, restricting relevant comparisons. Number of cycles resulting in EMT ≤7mm, and particularly ≤4mm, was limited, and consequently respective results should be interpreted cautiously.

Wider implications of the findings

Utilizing patients as their own controls, we showed that CC compared to gonadotropins resulted in thinner endometrium. Given comparable follicular response, and potentially estradiol levels, thinner endometrium might have resulted from CC’s anti-estrogenic effect. Furthermore, patients conceiving on CC had a thicker endometrium compared to the ones that did not.

Trial registration number

NA

P-434 Is there an association between pre-ovulatory estradiol levels and placental pathology of singleton livebirths conceived with gonadotropins/intrauterine insemination (Gn/IUI) treatments?

Study question

Is pre-ovulatory estradiol level associated with placental weight (PW) and abnormality rates (PAR) in singleton livebirths resulting from gonadotropins/intrauterine insemination (Gn/IUI) treatments?

Summary answer

In Gn/IUI-conceived, singleton-livebirths with available placental pathology, an association was noted between preovulatory estradiol levels and PW, but not between estradiol and PAR.

What is known already

Data suggest an association between ART and placental-mediated pregnancy complications, as well as increased rates of placental pathology. Supraphysiologic levels of preovulatory estradiol have been implicated in abnormal placentation. Whether such an effect is noted in Gn/IUI treatments, where levels of estradiol are lower, nevertheless supraphysiologic, remains unknown.

Study design, size, duration

We retrospectively reviewed data from 560 Gn/IUI-conceived, singleton-livebirths (1/2004-1/2021) recruited from a large academic fertility center. Placental pathology information was available from 218 cycles. These cycles were stratified by pre-ovulatory estradiol levels in quartiles [Q1(lower)-Q4 (higher)]. PW [grams & percentiles (%iles)], and rates of placental abnormalities (classified as anatomic, inflammatory, infectious, and vascular/thrombotic) were compared between groups.

Participants/materials, setting, methods

Participants: Women with Gn/IUI-conceived, singleton-livebirths with available placental pathology.

Outcome Measures: PW and PAR.

Statistics: Regression analysis was utilized to estimate the association of pre-ovulatory estradiol %iles with PW and PAR, adjusting for potential confounders (PW: maternal and gestational age, BMI, infertility diagnosis, medical complications, infant gender; PAR: maternal and gestational age, BMI, race). Adjusted Odds Ratios (OR) with 95%CI were calculated for the latter.

Main results and the role of chance

Mean PW(±SD) in grams were 477.3(±124.1), 445.9(±107.4), 451.2(±113.9), and 438.9(±107.0) in Q1 through Q4 (p=.368). Small placentas (≤10thPW %ile) accounted for more than a third of the total in all estradiol quartiles (37.5%, 49.2%, 37.5%, and 42.2%, p=.539, Q1-Q4, respectively). Similarly, increasingly higher percentages of placentas ≤25th PW %ile were noted with increasing estradiol quartiles (47.9%, 57.6%, 62.5% and 64.5%, in Q1-Q4 respectively, p=.347). After adjusting for potential confounders, we noted a mean 13.7 grams decrease in PW between each subsequent estradiol quartile [ adjβ-coeff (95%CI): -13.7(-27.7-0.3), p=.055]. When estradiol levels were analyzed as a continuous variable, an inverse association with PW [ adjβ-coeff (95%CI): -0.08 (-0.16-(-0.01)), p=.026] was noted. Adjusted ORs for small placenta did not differ between estradiol quartiles or when estradiol was analyzed as a continuous variable [adjORs(95%CI): 1.73(0.74-4.07), 1.10(0.47-2.55), 1.81(0.69-4.72), for Q2-Q4, Q1 as ref.; 1.001(1.000-1.003), p=.167; respectively].

There was no significant association between placental abnormality rates (PAR) and estradiol, either before or after adjustment [adjORs(95%CI): i) Anatomic : 1.16(0.49-2.74), 1.52(0.65-3.59), and 1.17(0.45-3.02); ii) Inflammatory : 0.40(0.13-1.25), 0.79(0.28-2.17), and 1.25(0.42-3.73); iii) Infectious : 0.89(0.35-2.25), 1.67(0.68-4.13), and 0.58(0.20-1.67); iv) Vascular/thrombotic : 0.88(0.37-2.08), 1.87(0.80-4.41), and 0.95(0.36-2.49); for Q2-Q4 vs. Q1].

Limitations, reasons for caution

There are several limitations, including the retrospective design, possible selection bias resulting from the decision to obtain placental pathology. Nonetheless, birth weights did not differ between those with and without placental pathology. Estradiol levels, albeit supraphysiologic, are much lower than those in ART and differences might be masked.

Wider implications of the findings

In Gn/IUI-conceived, singleton-livebirths with available placental pathology, an association was noted between preovulatory estradiol levels and placental weight, but not between estradiol and the rate of specific placental abnormalities (PAR). Since estradiol levels are lower than those observed in ART, an association might have been missed.

Trial registration number

not applicable

P-294 Use of Artificial Intelligence to Assess the Effects of Assisted Hatching on Embryo Development and Implantation Potential

Study question

Does the use of laser-assisted hatching (AH) on cleavage stage embryos affect in vitro preimplantation embryo development or implantation potential?

Summary answer

There is no difference in blastocyst conversion rate or implantation potential of embryos following AH at the cleavage stage for patients under age 35 years.

What is known already

Laser-AH is the process of creating an opening within the zona pellucida on cleavage stage embryos to facilitate biopsy of trophectoderm cells for preimplantation genetic testing (PGT). Studies have shown that PGT for aneuploidy (PGT-A) in patients under 35 years have reduced pregnancy rates compared to those not undergoing biopsy. This is attributed to the additional micromanipulation events involved with PGT-A may decrease the viability of embryos and compromise their implantation potential. We aimed to objectively compare the impact of AH on embryo development using an artificial intelligence (AI)-algorithm trained to assess embryo quality and predict developmental fate.

Study design, size, duration

A retrospective dataset from patients under 35 years was generated from two timepoints: cleavage stage embryos immediately before AH between 60-64 hours post insemination (hpi); and blastocyst stage embryos between 110-115 hpi prior to transfer or vitrification. Time-lapse imaging was obtained using the EmbryoScope (Vitrolife). Cleavage stage embryo images were used to train a convolutional neural networks (CNN) to predict and classify the development and implantation potential of cleavage and blastocyst stage embryos.

Participants/materials, setting, methods

Time-lapse images were collected for 1444 cleavage stage embryos spanning 189 in vitro fertilization (IVF) cycles between January 2014 – December 2021 at a single academic fertility center in Boston. Embryos were categorized into two groups: Day 3 embryos with AH (D3+AH) and without AH (D3-No AH). Each patient had a single blastocyst embryo transfer with a known outcome. Two-tailed t-tests were used to compare differences, with p-value less than 0.05 set for statistical significance.

Main results and the role of chance

The dataset included 1035 embryos with AH (D3+AH) and 409 embryos without AH (D3-No AH). There were no differences in AI-predicted blastocyst development between Day 3 embryos with AH and without AH (64.1% vs 64.1%) or AI-predicted high quality blastocyst development rate between these two groups (43.8% vs 40.8%), respectively. On Day 5 there were no differences in the AI-categorization of embryos at the blastocyst stage between embryos with or without AH (62.3% vs 62.5%) or AI-categorization of high-quality blastocyst development (45.2% vs 41.8%), respectively. AI predicted a similar implantation potential between embryos with and without AH at the cleavage stage (61.1% vs 69.9%). When stratifying to only the embryos transferred, there were no differences in the AI-predicted blastocyst development between Day 3 embryos with AH and without AH (96.0% vs 97.1%) or in the AI-predicted high quality blastocyst development rate between these two groups (72.0% vs 82.7%). AI predicted a similar implantation potential between embryos with and without AH at the cleavage stage (72.0% vs 69.0%). These results correspond with the true clinical pregnancy rate between the AH and Non-AH groups (68.0% vs 61.9%, p = 0.44).

Limitations, reasons for caution

These retrospective findings were of patients who had time-lapse imaging of cleavage stage and blastocysts available. Additionally, we focused on high prognosis patients that were eligible for single blastocyst stage embryo transfer. Clinical pregnancy rate was examined, not spontaneous abortion or live birth rates.

Wider implications of the findings

Utilization of AI technology allows for more objective and standardized methods for examining the impact of laboratory procedures on the developmental fate of embryos. This study demonstrated the safety of utilizing laser-assisted hatching on embryo development within this study population.

Trial registration number

None

P-426 Placental pathology following Intrauterine Insemination (IUI) with or without Ovarian Stimulation (OS)

Study question

Do placental weight percentiles (PW %iles) and abnormality rates (PAR) differ in singleton-livebirths following IUI with or without OS [oral medications (OM), and injectable gonadotropins]?

Summary answer

Following singleton-livebirths, PW did not differ between groups, albeit over half of placentas were ≤25th%ile. Placental anatomic abnormalities were more often seen in OM cycles.

What is known already

ART data suggest a possible association between stimulation-induced supraphysiologic estradiol levels and increased risk of placental abnormalities, as well as subsequent placental-mediated pregnancy complications, such as preeclampsia. Whether there is an association between OS protocols for IUI and placental pathology remains unknown.

Study design, size, duration

Data from 975 IUI(±OS) cycles resulting in singleton livebirths at a large academic fertility center between 01/2004 and 01/2021, were retrospectively reviewed. In 386 cycles a full placental pathologic examination was available. Placentas were stratified by OS regimen into three groups: gonadotropins (n = 222), OM [Clomiphene Citrate (CC)/Letrozole (LTZ); n = 129], and unstimulated / natural (n = 35). PW and PAR were compared between groups.

Participants/materials, setting, methods

Participants: Women delivering a singleton liveborn following IUI(±OS) treatments with placental pathology available.

Outcome Measures: PW (grs & %iles), and PAR (classified as anatomic, inflammatory, infectious, and vascular/thrombotic).

Statistics: Regression analysis was utilized to compare PW and PAR between groups, adjusting for potential confounders (PW: maternal and gestational age, BMI, infertility diagnosis, medical complications, infant gender; PAR: maternal and gestational age, BMI, race). Adjusted Odds Ratios (adjOR, 95%CI) were calculated for the latter.

Main results and the role of chance

Mean(±STDEV) PW (grs) were 451.7(±113.3), 449.2(±102.4), and 481.8(±99.8), for the gonadotropins, OM, and natural groups, respectively. Interestingly, over half of the placentas in all three groups were ≤25th %ile (58.6%, 56.1%, and 52.9%, for gonadotropins, OM, and natural, respectively, p=.249), while 41.8%, 46.4%, and 38.2% were below the 10th %ile (for gonadotropins, OM, and natural, respectively, p=.598). Adjusted PW differences, and adjOR for small placenta (≤10th %ile) did not differ between groups [PW OR(95%CI): 5.6(-17.9-29.2), -28.1(-71.4-15.2), -11.7(-52.6-29.3); small placenta OR(95%CI): 1.04(0.62-1.76); 1.27(0.40-4.01), and 0.96(0.34-2.74) for OM vs. gonadotropins, OM vs. natural, and gonadotropins vs. natural, latter as ref. ].

Regarding PAR, anatomic(43.7%, 52.7%, and 40%, p=.192), inflammatory(20.7%, 27.1%, and 20%, p=.354), infectious(32.9%, 33.3%, and 31.4%, p=.978), and vascular/thrombotic(42.3%, 41.9%, and 42.9%, p=.993) abnormalities rates did not differ between gonadotropins, OM, and natural, respectively. AdjORs(95%CI) for inflammatory, infectious, and vascular/thrombotic abnormalities did not differ significantly between groups. However, anatomic abnormalities were more frequent among OM compared to gonadotropin and natural cycles [adjOR(95%CI): 1.76(1.06-2.91), p=.028, gonadotropins as ref.; 2.52(1.05-6.05), p=.038, natural as ref.].

Limitations, reasons for caution

This study is limited by its retrospective nature. Unfortunately, placental pathology was available only in conceptions clearly identified as resulting from IUI(±OS) treatments. However, birth weights did not differ between those with and without available placental pathology. Natural/IUI cycles were limited in numbers not allowing meaningful conclusions.

Wider implications of the findings

Between IUI-conceived, singleton-livebirths with available placental pathology, mean PW did not differ significantly. However, a higher-than-expected percent of placentas were below the expected %iles, suggesting that IUI(±OS) might be associated with altered placental growth. Placental anatomic abnormalities were more common among OM cycles, compared to gonadotropins, and n atural IUI cycles.

Trial registration number

Not applicable

The effect of semen collection at home on intrauterine insemination outcomes

BACKGROUND

The WHO 2010 guidelines recognize at-home semen collection as an acceptable alternative to standard collection at the clinic in "exceptional circumstances". There is lack of sufficient data to determine the need for revisiting these recommendations for treatment purposes.

OBJECTIVES

To determine whether at home semen collection has any effect on intrauterine insemination (IUI) cycle outcomes.

MATERIALS AND METHODS

This is a retrospective cohort study of 729 IUI treatment cycles (382 patients) performed at an academic fertility center from 9/19/2019 to 12/31/2020. Semen collected at the "clinic" was used for 343 cycles before the Coronavirus Disease 2019 (COVID-19) pandemic (09/19/2019-3/21/2020), and "at-home" collected specimens were used for 386 cycles following revised protocols with COVID-19 driven changes (5/30/2020-12/31/2020). Logistic regression models were performed to evaluate the effect of "at-home" semen collection on achieving a positive pregnancy test (PPT) and a clinical pregnancy (CP).

RESULTS

Male and female partners' age, ovarian reserve biomarkers, and stimulation regimens used were similar in the "clinic" and "at-home" groups. In unadjusted models, "at-home" collection had no significant effect on the odds for a PPT [OR (95%CI): 0.733(0.503-1.069)] or CP [0.816(0.543-1.226)]. These results persisted even when adjusting for maternal age and anti-Müllerian Hormone: PPT [0.739(0.505-1.081)] and CP [0.826(0.547-1.248)]. Of the semen analysis parameters under evaluation, only motility appeared to significantly impact the odds of achieving a PPT [1.014(1.004-1.025)] and a CP [1.017(1.006-1.029)]. This effect was slightly attenuated for samples collected "at-home" [1.012(0.997-1.027) and 1.015(0.999-1.031), respectively for PPT and CP].

DISCUSSION

This study adds important information to the limited literature regarding the effect of at-home semen collection on IUI outcomes. Under adequate protocols, at-home semen collection should be considered a safe alternative. Additional research is needed to optimize such protocols.

CONCLUSION

Our data suggest that at-home semen collection does not negatively impact IUI pregnancy outcomes. This article is protected by copyright. All rights reserved.

Male waist circumference in relation to semen quality and partner infertility treatment outcomes among couples undergoing infertility treatment with assisted reproductive technologies

BACKGROUND

Male obesity has been related to poor semen quality and may also have a negative effect on assisted reproductive technologies (ART) outcomes. Whether male waist circumference (WC), as a measure of central obesity, impacts a couple's fertility independently of BMI is unclear.

OBJECTIVES

To examine the associations of male WC with semen quality and couples' outcomes of infertility treatment with ART.

METHODS

Couples presenting to the Massachusetts General Hospital Fertility Center were invited to participate in the study. Between 2009 and 2019, 269 males provided 671 semen samples and 176 couples underwent 317 ART cycles. Height, weight, and WC were measured on site. We analyzed the association of male WC with semen quality and pregnancy outcomes using cluster-weighted regression models to account for repeated observations while adjusting for potential confounders. Models were also stratified by male BMI (<25 kg/m2 compared with ≥25 kg/m2).

RESULTS

The median male age, WC, and BMI were 36.1 years, 96.0 cm, and 26.8 kg/m2, respectively. A 5-cm increase in WC was associated with a 6.3% (95% CI, 2.1-10.5%) lower sperm concentration after adjustment for potential confounders, including BMI. Male WC was also inversely related to the probability of achieving a live birth. For each 5-cm increase in male WC, the odds of a live birth per initiated cycle decreased by 9.0% (95% CI, 1.1%-16.4%) after accounting for several anthropometric and demographic characteristics of both partners. These associations were stronger among males in the normal BMI category (<25 kg/m2) than among overweight or obese males.

CONCLUSIONS

A higher male WC may be an additional risk factor for poor outcomes of infertility treatment, even after accounting for male and female partner BMIs, particularly in couples where the male partner has a normal BMI.

Paternal adherence to healthy dietary patterns in relation to sperm parameters and outcomes of assisted reproductive technologies

OBJECTIVE

To investigate whether men's adherence to dietary patterns promoted for the prevention of cardiovascular disease is associated with semen parameters and couples' assisted reproductive technology (ART) outcomes.

DESIGN

Prospective cohort study.

SETTING

Fertility center at an academic medical center.

PATIENT(S)

A total of 245 men and their female partners who underwent 438 ART cycles between 2007 and 2020.

INTERVENTION(S)

Male pretreatment dietary intake was assessed with a 131-item food frequency questionnaire from which we calculated eight a priori defined scores: Trichopoulou Mediterranean, Alternate Mediterranean, Panagiotakos Mediterranean, Healthy Eating Index, Alternative Healthy Eating Index, American Heart Association, Dietary Approaches to Stop Hypertension, and Plant-based.

MAIN OUTCOME MEASURE(S)

The primary outcome was live births per treatment cycle. The secondary outcomes were fertilization, implantation, and clinical pregnancy and seminogram parameters.

RESULT(S)

There was an inverse association between greater adherence by men to the Panagiotakos Mediterranean diet and the American Heart Association dietary pattern and lower fertilization rate. However, there were no significant associations between men's adherence to any of the analyzed dietary patterns and the probabilities of implantation, clinical pregnancy, or live birth in multivariable-adjusted models. No significant differences in any of the semen parameters were found between participants of the lowest quartile and those of the highest quartile of the eight dietary patterns.

CONCLUSION(S)

These findings suggest that men's adherence to several a priori defined dietary scores with documented cardiovascular benefits is not related to major outcomes of infertility treatment with ART or semen quality.

A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence

OBJECTIVE

To estimate the probability of clinical or multiple pregnancy during ovulation induction (OI)/ovarian stimulation (OS).

DESIGN

Secondary analysis of two multicenter randomized clinical trials (combined).

SETTING

Multicenter.

PATIENTS

A total of 750 women with polycystic ovary syndrome and 900 women with unexplained infertility.

INTERVENTIONS

Ovulation induction/OS with either timed intercourse (polycystic ovary syndrome) or intrauterine insemination.

MAIN OUTCOME MEASURES

Clinical and multiple pregnancy rates/cycle, cumulative pregnancy rates. Age, body mass index, parity, diagnosis, medication, markers of ovarian reserve, and ovarian response were considered in multivariable regression models for clinical, multiple, and cumulative pregnancy rates. Receiver operating characteristic curves were created for clinical and multiple pregnancy rates.

RESULTS

Younger patient and partner age, treatment type, lower body mass index, and medication dose were all associated with clinical pregnancy. Variables associated with multiple pregnancy included the abovementioned variables (except age), in addition to diagnosis, parity, higher antral follicle count, antimüllerian hormone levels, and ovarian response. Gonadotropin use was associated with multiple pregnancy, with progressively increasing odds ratios (cycles 1-4). Receiver operating characteristic curves indicated the model's predictive power to be fair for clinical pregnancy (areas under the curve [95% confidence interval {CI}]: 0.78 [0.75-0.81] for cycle 1 and 0.70 [0.64-0.75] for cycle 4) and good-to-excellent for multiple pregnancy (areas under the curve [95% CI]: 0.78 [0.72-0.84] for cycle 1 and 0.86 [0.78-0.93] for cycle 4). Partner age, lower medication dose, parity, antimüllerian hormone levels, and diagnosis were associated with cumulative pregnancy rates.

CONCLUSIONS

Using the majority of the factors known to predict the outcome of OI/OS cycles, we constructed an easy-to-use formula that may predict individualized chances of clinical and multiple pregnancy for commonly used fertility treatments (https://pregnancyprediction.medicine.yale.edu/CalDirect.html).

CLINICAL TRIAL REGISTRATION NUMBERS

Assessing Multiple Intrauterine Gestations after Ovulation Stimulation NCT01044862; PPCOSII NCT00719186.

Placental pathology of term singleton live births conceived with fresh embryo transfer compared with those conceived without assisted reproductive technology

OBJECTIVE

To compare placental pathology from term singleton live births conceived with fresh embryo transfer vs. those conceived without assisted reproductive technology (ART).

DESIGN

Retrospective cohort study.

SETTING

Academic fertility center.

PATIENT(S)

Women with a term singleton live birth who conceived after fresh autologous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles (ART group) and those who conceived without ART.

INTERVENTION(S)

An experienced placental pathologist categorized placental pathology as anatomic, inflammatory, or vascular. Patient characteristics were compared by chi-squared tests, Student's t-test, or nonparametric tests. Multivariate logistic regression models were used to compare placental pathology between pregnancies conceived with and without ART.

MAIN OUTCOME MEASURE(S)

Incidence of anatomic, inflammatory, and vascular placental pathology.

RESULT(S)

There was a higher incidence of placental pathology in the ART group (n = 511) than in the non-ART group (n = 121), specifically anatomic (adjusted odds ratio [aOR] 2.50, 95% confidence interval [CI] 1.42-4.40) and vascular (aOR 2.00, 95% CI 1.13-3.53) pathology. These findings were driven primarily by the significantly higher odds of anatomic (aOR 2.97, 95% CI 1.55-5.66) and vascular (aOR 1.98, 95% CI 1.04-3.75) pathology observed in ICSI pregnancies. Single blastocyst transfers remained associated with increased anatomic pathology (ART: aOR 4.89, 95% CI 2.28-10.49; ICSI: aOR 3.38, 95% CI 1.49-7.71).

CONCLUSION(S)

Fresh embryo transfer is associated with increased anatomic and vascular placental pathology in term singleton live births compared with conception without ART. This finding should be investigated prospectively in a larger cohort of patients.

Phthalate and DINCH urinary concentrations across pregnancy and risk of preterm birth

Preconception and prenatal exposure to phthalates has been associated with an increased risk of preterm birth. However, it is unclear whether there are periods of heightened susceptibility during pregnancy. This prospective cohort study included 386 women undergoing fertility treatment who gave birth to a singleton infant during 2005 through 2018. Eleven phthalate metabolites were measured in spot urine samples collected at each trimester. In approximately 50% of participants, two metabolites of 1,2-cyclohexane dicarboxylic acid diisononyl ester (DINCH), a phthalate substitute, were also measured. The molar sum of four di(2-ethylhexyl) phthalate metabolites (∑DEHP) was calculated. We evaluated the associations of mean maternal biomarker concentrations with risk of preterm birth using modified log-binomial models and utilized multiple informant models to compare trimester-specific associations. We examined the relative biomarker concentration across gestation comparing women with preterm birth to women with term delivery using quadratic mixed model. The risk ratio for preterm birth associated with a one-unit increase in the natural log-transformed urinary concentrations of ∑DEHP (mean during pregnancy) was 1.21 (95% confidence interval (CI): 0.84, 1.72). In multiple informant models, these associations were strongest in the third trimester (RR = 1.51; 95% CI: 1.17, 1.95). Estimated mean ∑DEHP concentrations were higher among women with preterm than term delivery, especially late in gestation. Associations with preterm birth were also observed for each of the four individual DEHP metabolites. Detection of cyclohexane-1,2-dicarboxylic acid monocarboxyisooctyl ester (MCOCH), a metabolite of DINCH, appeared to be positively related to preterm birth. In this prospective cohort of subfertile couples, maternal ∑DEHP metabolite concentrations during pregnancy were associated with an increased risk of preterm birth, particularly during late gestation.

Folate intake and ovarian reserve among women attending a fertility center

OBJECTIVE

To examine the association between dietary folate intake and antral follicle count (AFC) among women seeing treatment for infertility.

DESIGN

Cohort study.

SETTING

Academic fertility center.

PATIENTS

A total of 552 women attending the Massachusetts General Hospital Fertility Center (2007-2019) who participated in the Environment and Reproductive Health Study.

INTERVENTIONS

None. Folate intake was measured with a validated food frequency questionnaire at study entry. Multivariable Poisson regression models with robust standard errors were used to estimate the association of folate intake with AFC adjusting for calorie intake, age, body mass index, physical activity, education, smoking status, year of AFC, and intakes of vitamin B₁₂, iron, and vitamin D. Nonlinearity was assessed with restricted cubic splines.

MAIN OUTCOME MEASURE

AFC as measured by transvaginal ultrasonography as part of routine care.

RESULTS

Among the 552 women (median age, 35.0 years; median folate intake, 1,005 μg/d), total and supplemental folate intake had a significant nonlinear relationship with AFC. There was a positive linear association with AFC up to approximately 1,200 μg/d for total folate intake and up to 800 μg/d for supplemental folate intake; however, there was no additional benefit of higher folate intakes. The magnitude of the association was modest; for example, the predicted adjusted difference in AFC between a woman consuming 400 vs. 800 μg/d of supplemental folate was approximately 1.5 follicles.

CONCLUSION

Higher intake of folate, particularly from supplements, was associated with modestly higher ovarian reserve as measured by AFC among women attending a fertility center.

CLINICAL TRIAL REGISTRATION NUMBER

This trial was registered at clinicaltrials.gov as NCT00011713.

A dietary score representing the overall relation of men's diet with semen quality in relation to outcomes of infertility treatment with assisted reproduction

Objective

To examine the impact of men's diet on outcomes of infertility treatment with assisted reproductive technology (ART) using an empirical score representing the relation of diet with semen quality.

Design

Prospective cohort study.

Setting

Fertility center at an academic medical center.

Patients

We included 296 men (688 semen samples) to identify an empirical dietary pattern and 231 couples (406 ART cycles) to investigate the association of this diet pattern with ART outcomes.

Interventions

Men's diet was assessed at baseline using a validated questionnaire. An empirical dietary pattern reflecting the overall relation of diet with semen quality was identified using reduced rank regression.

Main Outcome Measures

The primary outcome was live birth per treatment cycle. The secondary outcomes were fertilization, implantation, and clinical pregnancy.

Results

Men had a median baseline age and body mass index of 36.8 years and 26.9 kg/m², respectively. Although the empirical diet pattern was significantly associated with all semen parameters, the empirical diet score was not related to any clinical outcome of infertility treatment after ART. The adjusted probabilities of relevant clinical outcomes in the lowest and highest quartiles of the empirical score were 0.62 (0.50-0.73) and 0.55 (0.45-0.66) for implantation, 0.57 (0.46-0.69) and 0.50 (0.40-0.61) for clinical pregnancy, and 0.49 (0.37-0.62) and 0.36 (0.25-0.48) for live birth. Analyses excluding couples with a diagnosis of male factor infertility and, separately, excluding intracytoplasmic sperm injection cycles yielded similar results.

Conclusions

A dietary score representing the overall association of diet with semen quality parameters was not associated with ART outcomes.

Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment

Exposure to phthalates, endocrine-disrupting chemicals commonly used as plasticizers and in consumer products, has been associated with infertility and premature ovarian failure. Our objective was to investigate whether urinary phthalate metabolite concentrations were associated with pre-ovulatory follicular fluid (FF) anti-müllerian hormone (AMH) concentrations in women undergoing fertility treatment. This cross-sectional analysis included 138 women with urinary phthalate data available in the Environment and Reproductive Health (EARTH) Study (2010-2016) in whom FF AMH concentrations were quantified using a sandwich enzyme-linked immunosorbent assay (ELISA). We also quantified 8 phthalate metabolite concentrations using tandem mass spectrometry in 1-2 urine samples per cycle (total 331 urines) and calculated the cycle-specific geometric mean for each metabolite. We applied cluster-weighted generalized estimating equation models (CWGEE) to evaluate the associations of tertiles of urinary phthalate metabolite concentrations with log-transformed FF AMH concentrations adjusting for potential confounders. Study participants had median age of 34.0 years (IQR 32.0, 37.0), 83% were white, and median BMI of 23.1 kg/m² (IQR 21.2, 26.1). The following stimulation protocols were used: luteal phase agonist (70%), antagonist (14%), or flare (16%). Urinary concentrations of select phthalate metabolites were negatively associated with FF AMH. For example, women whose urinary mEOHP was in the lowest tertile (range 0.30-4.04 ng/ml) had an adjusted mean FF AMH of 0.72 ng/mL (95% CI = 0.36, 1.44), compared to women in the highest tertile (range 9.90-235), who had an adjusted mean of 0.24 ng/mL (95% CI = 0.12-0.48, p < 0.05). The negative association between urinary concentrations of certain phthalate metabolites with FF AMH concentrations may have implications for antral follicle recruitment and fertility treatment outcomes.